High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism
Top Cited Papers
- 17 August 2000
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 343 (7) , 457-462
- https://doi.org/10.1056/nejm200008173430702
Abstract
A high plasma level of factor VIII is a risk factor for venous thromboembolism. We evaluated the risk of a recurrence of thrombosis after an initial episode of spontaneous venous thromboembolism among patients with high plasma levels of factor VIII. We studied 360 patients for an average follow-up period of 30 months after a first episode of venous thromboembolism and discontinuation of oral anticoagulants. Patients who had recurrent or secondary venous thromboembolism, a congenital deficiency of an anticoagulant, the lupus anticoagulant, hyperhomocysteinemia, cancer, or a requirement for long-term treatment with antithrombotic drugs or who were pregnant were excluded. The end point was objectively documented, symptomatic recurrent venous thromboembolism. Recurrent venous thromboembolism developed in 38 of the 360 patients (10.6 percent). Patients with recurrence had higher mean (±SD) plasma levels of factor VIII than those without recurrence (182±66 vs. 157±54 IU per deciliter, P=0.009). The relative risk of recurrent venous thrombosis was 1.08 (95 percent confidence interval, 1.04 to 1.12; P<0.001) for each increase of 10 IU per deciliter in the plasma level of factor VIII. Among patients with a factor VIII level above the 90th percentile of the values in the study population, the likelihood of recurrence at two years was 37 percent, as compared with a 5 percent likelihood among patients with lower levels (P<0.001). Among patients with plasma factor VIII levels above the 90th percentile, as compared with those with lower levels, the overall relative risk of recurrence was 6.7 (95 percent confidence interval, 3.0 to 14.8) after adjustment for age, sex, the presence or absence of factor V Leiden or the G20210A prothrombin mutation, and the duration of oral anticoagulation. Patients with a high plasma level of factor VIII have an increased risk of recurrent venous thromboembolism.Keywords
This publication has 32 references indexed in Scilit:
- The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin MutationNew England Journal of Medicine, 1999
- A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous ThromboembolismNew England Journal of Medicine, 1999
- Recurrence of venous thromboembolism in patients with familial thrombophiliaArchives of internal medicine (1960), 1997
- The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous ThromboembolismNew England Journal of Medicine, 1997
- A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous ThromboembolismNew England Journal of Medicine, 1995
- The Management of Thrombosis in the Antiphospholipid-Antibody SyndromeNew England Journal of Medicine, 1995
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Hereditary deficiency of antithrombin III, protein C and protein SBlood Coagulation & Fibrinolysis, 1992
- Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED InvestigatorsJAMA, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958